Zentalis closes 26,450,000-share public offering at $3.5 per share, raises $92.6 million gross
ZNTL•Underwriting syndicate
TD Cowen, Guggenheim Securities and Oppenheimer served as joint bookrunners. H.C. Wainwright was passive bookrunner.
Proceeds to support azenosertib development
Net proceeds are earmarked for development of azenosertib, including clinical work, manufacturing, regulatory support and working capital.
Public offering closes with full option exercise
Zentalis closed an underwritten public offering of 26,450,000 common shares at $3.5 each.
The underwriters fully exercised a 3,450,000-share option; gross proceeds totaled about $92.6 million.
